Last reviewed · How we verify
Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants
This is a randomized, double-blind, placebo-controlled, dose-escalation study in healthy Chinese subjects at single dose administration of Allisartan Isoproxil Tablets (240 mg ,480 mg or 720 mg）or placebo. The study design allows an assessment of 3 doses with safety monitoring and PK sampling to evaluate the safety, tolerability and PK profile of Allisartan Isoproxil Tablets.
Details
| Lead sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
|---|---|
| Phase | PHASE4 |
| Status | RECRUITING |
| Enrolment | 54 |
| Start date | Sat Sep 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Feb 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy Participants
Interventions
- Allisartan Isoproxil Tablets 240mg or placebo
- Allisartan Isoproxil Tablets 480mg or placebo
- Allisartan Isoproxil Tablets 720mg or placebo
Countries
China